ストックスクリーナーアプリを入手
2.13
7.39%
-0.17
前日終値:
$2.30
開ける：
$2.27
24時間の取引高:
122.71K
Relative Volume:
0.07
時価総額：
$6.61M
収益：
$1.38M
当期純損益:
$-179.05M
株価収益率:
-0.3469
EPS:
-6.14
ネットキャッシュフロー:
$-155.03M
1週間 パフォーマンス:
-7.79%
1か月 パフォーマンス:
+494.97%
6か月 パフォーマンス:
+213.01%
1年 パフォーマンス:
-32.38%
1日の値動き範囲:
$2.10
$2.30
1週間の範囲:
$2.10
$2.60
52週間の値動き範囲:
$0.16
$3.50
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
名前
Bioxcel Therapeutics Inc
セクター
電話
203-643-8060
住所
555 LONG WHARF DRIVE, NEW HAVEN, CT
BTAI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
2.13 | 6.61M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-21 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-15 | ダウングレード | Mizuho | Buy → Neutral |
| 2023-07-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-03-10 | ダウングレード | Jefferies | Buy → Hold |
| 2022-12-01 | アップグレード | Goldman | Sell → Neutral |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-04-06 | 繰り返されました | BofA Securities | Buy |
| 2021-11-15 | ダウングレード | Goldman | Neutral → Sell |
| 2021-04-09 | 開始されました | Berenberg | Buy |
| 2021-02-01 | 開始されました | UBS | Buy |
| 2020-10-30 | 開始されました | Goldman | Buy |
| 2020-09-02 | 開始されました | Jefferies | Buy |
| 2020-08-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-04 | 開始されました | Guggenheim | Buy |
| 2020-04-01 | 開始されました | BofA/Merrill | Buy |
| 2020-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
すべてを表示
Bioxcel Therapeutics Inc (BTAI) 最新ニュース
BTAI stock plunges to 52-week low of $2.16 amid market challenges - Investing.com Nigeria
BioXcel Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
BioXcel Therapeutics expands board, appoints new director - MSN
BioXcel Therapeutics announces 1-for-16 reverse stock split - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Update - MarketBeat
BTAI stock touches 52-week low at $2.53 amid sharp annual decline - MSN
A significant driver of top-line growth: BioXcel Therapeutics Inc (BTAI) - SETE News
You Should Look At The Stock Forecast For BioXcel Therapeutics Inc (NASDAQ: BTAI). - Marketing Sentinel
BioXcel Therapeutics Inc (BTAI) Shares Down Despite Recent Market Volatility - The News Heater
The Psychology of BioXcel Therapeutics Inc Inc. (BTAI) Price Performance: Understanding Market Sentiment - The InvestChronicle
Balance Sheet Insights: BioXcel Therapeutics Inc (BTAI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential - Marketscreener.com
BioXcel Therapeutics, Inc. Appoints June Bray to its Board of Directors -March 01, 2021 at 10:13 am EST - Marketscreener.com
BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Senior Vice President and Chief Development Officer - Marketscreener.com
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation -February 12, 2024 at 07:43 am EST - Marketscreener.com
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts BioXcel Therapeutics (BTAI) Investors to Pending Securities Fraud Class Action, Encourages Investors with Substantial Losses to Contact Firm’s Attorneys - ACCESS Newswire
BioXcel Therapeutics enacts 1-for-16 reverse stock split - MSN
BioXcel Therapeutics announces reverse stock split - Hartford Business Journal
BioXcel Therapeutics announces 1-for-16 reverse stock split By Investing.com - Investing.com Nigeria
BioXcel to execute 1-for-16 reverse stock split - MSN
BioXcel to Implement Reverse Stock Split; Shares Fall -February 06, 2025 at 01:28 pm EST - Marketscreener.com
BioXcel Therapeutics Announces Reverse Stock Split - citybiz
BioXcel Therapeutics enacts 1-for-16 reverse stock split By Investing.com - Investing.com Canada
BioXcel Therapeutics Sets 1-for-16 Reverse Stock Split To Regain Nasdaq Listing - Nasdaq
BioXcel's Strategic Reverse Split: Critical Move to Preserve Nasdaq StatusWhat's at Stake - StockTitan
BioXcel Therapeutics advances key clinical trials - Investing.com India
BioXcel Therapeutics Inc (BTAI) Shares Plummet Below 1-Year High - The News Heater
BioXcel Therapeutics advances key clinical trials By Investing.com - Investing.com South Africa
BioXcel Therapeutics Provides Clinical and Business Update -February 05, 2025 at 07:45 am EST - Marketscreener.com
BioXcel Therapeutics Provides Clinical and Business Update - The Manila Times
Clinical Progress Alert: BioXcel's Strategic Moves in Agitation Treatment Trials Gain Momentum - StockTitan
BioXcel Therapeutics, Inc. Provides Clinical and Business Update -February 05, 2025 at 07:00 am EST - Marketscreener.com
Observations on the BioXcel Therapeutics Inc (NASDAQ:BTAI) Growth Curve - US Post News
What is HC Wainwright’s Forecast for BTAI FY2024 Earnings? - Defense World
BioXcel Therapeutics Holds Special Meeting, Approves Reverse Stock Split Plan - Defense World
HC Wainwright Cuts BioXcel Therapeutics (NASDAQ:BTAI) Price Target to $3.00 - Defense World
BioXcel Therapeutics stock hits 52-week low at $0.3 - MSN
BioXcel Therapeutics stock hits 52-week low at $0.3 By Investing.com - Investing.com Australia
Bioxcel Therapeutics Inc (BTAI) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):